About this trial
This study is a Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-Line or Third-Line Treatment for Participants with Recurrent or Metastatic Cervical Cancer.
Patient Profile
Patients with Recurrent or Metastatic Cervical Cancer who have received one prior line of platinum chemotherapy (doublet) plus anti-PD/L1 inhibitor.
Where’s this trial being run?
Cork University Hospital, St James’s Hospital, and Mater Misericordiae University Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | ENGOT cx20 |
|---|---|
| Number: | 24-10 |
| Full Title: | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) |
| Principal Investigator: | Dr. Dearbhaile Collins |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | MSD |
| Recruitment Started: |
Global: July 2024 Ireland: November 2024 |
| Global Recruitment Target: | 686 |
|---|---|
| Ireland Recruitment Target: | 12 |